# **1** Continued T12 transmission and shared antibiotic resistance during 2018-2023 *Vibrio*

# 2 cholerae outbreaks in Cameroon

3 Sen Claudine Henriette Ngomtcho<sup>1,2,3</sup>, Blaise Mboringong Akenji<sup>1,4</sup>, Roland Ndip<sup>4</sup>, Andrew S Azman<sup>5,6,7</sup>, Yanick Carolle

4 Tayimetha<sup>8</sup>, Etienne Guenou<sup>8</sup>, Sylvain Engamba<sup>8</sup>, Marie Claire Assoumou Okomo<sup>1</sup>, Justin Lessler<sup>5,9,10</sup>, Shirlee Wohl<sup>5,11</sup>

#### 5

- 6 <sup>1</sup>Molecular Biology Unit, National Public Health Laboratory, Yaoundé, Cameroon
- <sup>7</sup> <sup>2</sup>Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences, University
- 8 of Dschang, Dschang, Cameroon
- 9 <sup>3</sup>Genomic Surveillance Study Group, Ministry of Public Health, Yaoundé, Cameroon
- <sup>4</sup>Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon
- <sup>5</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 12 <sup>6</sup>Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland
- <sup>13</sup> <sup>7</sup>Division of Tropical and Humanitarian Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland
- 14 <sup>8</sup>Bacteriology Unit, National Public Health Laboratory, Yaoundé, Cameroon
- <sup>9</sup>Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Department of Epidemiology,
- 16 Chapel Hill, NC, USA
- <sup>10</sup>The Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 18 <sup>11</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA
- 19
- 20 Correspondence: swohl@bwh.harvard.edu (S.W.), ngomtchosen@gmail.com (S.C.H.N.)
- 21
- 22

## 23 ABSTRACT

Seventh pandemic Vibrio cholerae was first identified in Cameroon in 1971, causing several sporadic disease 24 clusters with few cases. More recent years have seen larger cholera outbreaks, but the mechanism behind these 25 periodic outbreaks is poorly understood, and it is unclear the degree to which antibiotic resistant strains contribute 26 to disease burden and spread. We used whole genome sequencing to characterize 14 V. cholerae isolates from the 27 2020 and 2021-2023 cholera epidemics in Cameroon. All these isolates belonged to the T12 lineage, and most 28 29 showed the same antimicrobial resistance (AMR) pattern regardless of year. This suggests that cholera outbreaks in Cameroon are, at least in part, a continuation of the outbreaks previously reported in 2018 and as far back as 30 2012. This finding has important implications for cholera management since it suggests the ongoing presence of 31 pathogenic cholera even in years with few reported cases. Similarly, the AMR results suggest the need for new 32 treatment approaches, as resistance to many common antibiotics was found even within our limited sample set. 33 As such, whole genome sequencing should be implemented in low-income countries such as Cameroon to improve 34 disease surveillance and to detect and predict pathogen antibiotic resistance profiles. 35

## 36 INTRODUCTION

37 Since the first documented cholera pandemic in 1817, seven *Vibrio cholerae* pandemics have been recorded [1].

38 The seventh pandemic originated in Southeast Asia in 1961 and is still ongoing. It reached the African continent

in 1970, first affecting West African countries (Guinea-Bissau and Guinea Conakry), and then reaching Central

40 Africa, and specifically Cameroon, in 1971 [2, 3]. Despite having been cholera-free before 1970, Africa now bears

the major burden of the global cholera cases, with over 4 million cholera cases and 143,000 deaths reported in

42 Africa per year [2].

Cameroon reported its first cholera cases in February 1971. This was followed by a 20-year period characterized by sporadic disease clusters with few cases. Following this period, larger outbreaks were reported in 1991, 1996, 1998, 2004, 2010, 2011, and over 46,000 suspected cholera cases and 1,800 deaths were reported between 2004 and 2013 [4]. Minimal cases were reported in intervening years, and the mechanism behind these periodic cholera outbreaks remains poorly understood. Specifically, it is unclear if successive outbreaks are caused by sustained

48 circulation of existing strains, or if each is caused by a new introduction.

More recent cholera outbreaks in Cameroon have followed a similar trend, despite increased efforts to improve surveillance nationwide. On May 18, 2018, two suspected cases of cholera were reported in the North Region of

51 Cameroon and ultimately confirmed as *Vibrio cholerae* by bacterial culture. Cases associated with this outbreak

52 spread into the Far North Region and continued until December 2019, resulting in a total of 1212 suspected cases

and a 5.1% case fatality rate (CFR) in the North Region and 350 cases (CFR: 4.6%) in the Far-North [5].

After a brief period of few cases, the Ministry of Health in Cameroon declared another outbreak following 54 laboratory confirmation of Vibrio cholerae in late January 2020. 18 health districts were affected in four 55 neighboring administrative regions (South-West, Littoral, South and Center) and the outbreak lasted throughout 56 the final weeks of 2020, causing 1892 cases (CFR: 4.2%) [6]. After several months of minimal cases (<200 in 57 total), a new outbreak was declared in Cameroon on October 29, 2021. As of October 2023, over 21,000 suspected 58 cases have been reported (CFR: 2.4%) (Supplementary Data 1) [7]. This 2023 epidemic has spread to the six 59 main regions of the country, with the central Littoral Region becoming the epicenter of the epidemic. 60 Understanding how each of these outbreaks spread and the relationship between them may inform approaches to 61 cholera containment in Cameroon and have implications for outbreak management elsewhere. 62

Molecular characterization of seventh pandemic V. cholerae may be one important tool for understanding cholera 63 outbreak emergence and spread. Already, genomic data has led to new insights about global cholera transmission 64 and has highlighted the important role of transmission within and between Asia and Africa [8, 9]. Combining 65 genomic and epidemiological data has allowed scientists to better understand the dynamics of ongoing outbreaks, 66 and advances in sequencing technology have recently made whole genome sequencing more feasible even in low-67 resource settings. Previous studies initially identified three waves of seventh pandemic V. cholerae [10] which 68 were later broken down into at least 14 plausible introduction events from Asia into Africa, termed T1–T14 [8, 9, 69 70 11]. These lineages can be used to identify the approximate source of case clusters; for example, cases caused by 71 the same lineage as a previous outbreak might suggest undetected sustained transmission, while identification of

a new lineage could suggest that new cases were caused by a new international introduction.

73 Even so, identification of *V. cholerae* strains responsible for cholera in Cameroon epidemics has been largely

<sup>74</sup> limited to bacteriological culture, without more advanced molecular analyses like whole genome sequencing [12].

To better understand the cholera dynamics in Cameroon and Sub-Saharan Africa as a whole, we characterized *V*.

*cholerae* O1 isolates from the 2018-2019, 2020, and 2021-2023 (still ongoing) epidemics, with the goal of

identifying and comparing the *V. cholerae* lineages in circulation in Cameroon, and ultimately using this

<sup>78</sup> information to better understand cholera transmission dynamics in order to prioritize public health action. As

antimicrobial resistance is becoming an increasingly serious threat to public health [13], we also determined the

antimicrobial resistance profile of these samples, in the hopes of providing information that can be used to limit

81 the spread of pathogenic drug-resistant *V. cholerae*.

#### 82 **RESULTS**

To better understand V. cholerae transmission patterns in Cameroon, we sequenced 55 isolates from 83 epidemiological and laboratory-confirmed cases from the 2018, 2020 and 2021 epidemics (Table 1). We selected 84 these isolates to ensure representation as many regions of Cameroon as possible (samples were sequenced from 85 eight of the ten regions of Cameroon, see Figure 1). We sequenced these isolates at the National Public Health 86 87 Laboratory in Cameroon using the Oxford Nanopore platform and generated whole genome sequences (>97% reference genome coverage) from 14 of the 55 isolates (25% success rate) (Supplementary Data 1). Although 88 89 we successfully obtained sequences from six included regions, none of the isolates from the 2018 epidemic achieved our 97% coverage threshold and were therefore excluded from phylogenetic analysis. We observed 90 91 higher sequencing success rate from samples from the most recent epidemics, perhaps due to contamination issues associated with poor long-term storage conditions of older samples. 92

Year	Isolates Available	Isolates Sequenced	High quality Genomes	Disc Diffusion Results	Sequenced + Disc Diffusion	High quality + Disc Diffusion
2019	29	2	0	2	2	0
2020	30	20	4	9	9	3
2022	28	22	9	10	10	5
2023	43	11	1	33	0	0
TOTAL	130	55	14	54	21	8

93 Table 1. Isolates selected for sequencing and antimicrobial resistance phenotyping.





Figure 1. Spatial distribution of *V. cholerae* isolates selected for sequencing. Blue: high quality genomes included in downstream analyses; white: sequenced isolates that did not produce high quality genomes (see also **Supplementary Data 2**). The number of cholera cases reported between 18 May 2018 – 17 October 2023 are shown in shades of red.

We generated a maximum likelihood tree using the 14 successful sequences to better understand how *V. cholerae* O1 was circulating in Cameroon over time and space (Figure 2). Combining these sequences with previously published global *V. cholerae* genomes demonstrated that they belonged to the T12 lineage [9], which was shown to be circulating in Cameroon as recently as 2018 [12] and is the only lineage to have been observed in Cameroon since 2009 (Figure 2, see also Supplementary Data 3). Sequences from both 2020 and 2022 are found in this lineage, with no evidence for sequences belonging to other lineages.

Combined with the results presented in Ekeng et al., our observation of T12 sequences in both the 2020 and 2021 outbreaks provides strong evidence for continuous circulation of this lineage within Cameroon.

113 From our data, it is clear that the T12 lineage is even more widespread than previously thought, as we observed

this lineage in three new epidemiological areas: the North West, West, and South Regions (previously published

sequences from the 2018 outbreak were exclusively from the North, Littoral and Center Regions of the country)

- 116 (Figure 2). The new sequences generated in this study form two distinct Cameroon-specific sub-clusters that both
- 117 contain 2020 and 2022 sequences—as well as sequences from multiple regions of the country— suggesting
- circulation and evolution within Cameroon during the 2020 and 2021 outbreaks. These sub-clusters appear to be
- descendants of the West Africa T12 sub-cluster from 2018, supporting prior evidence for transmission between
- 120 the neighboring countries of Nigeria, Niger, and Cameroon.



121

Figure 2. Maximum likelihood tree of the V. cholerae T12 lineage. Sequences generated in this study cluster together and are shown in dark blue. Previously generated sequences from Cameroon are shown in light blue, and other previously generated sequences from the T12 lineage are shown in gray. Groups of newly generated sequences are labeled by the region in Cameroon the corresponding isolates were collected in (NW = North West). Scale bar: nucleotide substitutions per site.

To understand sequenced isolates that did not generate a high-quality *V. cholerae* O1 genome, we looked more closely at samples that generated a large number of reads that did not map to the N16961 *V. cholerae* O1 reference sequence. We identified 24 samples that generated at least 39,000 reads (the minimum number of reads used to assemble a high-quality *V. cholerae* O1 genome in samples sequenced as part of this study) that were ultimately excluded from our analysis. Of these, more than half were completely missing the ctxA gene, according to the typing results (**Supplementary Data 1**). Although poor sequencing quality may still explain these results, the existence of potential non-O1 *V. cholerae* among these isolates should not be excluded.

- 133 We also explored the results of antimicrobial resistance (AMR) testing to better understand the relationship
- between isolates. We performed AMR testing on 54 isolates (including 13 of the 14 that produced *V. cholerae*
- 135 O1 whole genome sequences) using disk-diffusion methods (Supplementary Data 4). We found that resistance
- 136 to most of the antibiotics tested was mixed (except for erythromycin, to which nearly all tested isolates were
- 137 resistant), and that these results did not cluster by time or place of sample collection. This finding highlights

138 why doxycycline, tetracycline, and ciprofloxacin are some of the primary antibiotics used to combat cholera

disease in Cameroon, though approximately 50% of isolates tested in this study were resistant to doxycycline

and/or tetracycline (55% and 50%, respectively), suggesting a need for continued monitoring of AMR, including

141 the extent to which AMR phenotype may correlate with genetic signatures.

### 142 **DISCUSSION**

Our finding of the T12 lineage in both 2020 and 2022 in Cameroon supports previous evidence suggesting continuous circulation of the lineage in the country (or at least in the region) since it was first observed in 2009.

This suggests that cholera containment efforts should, at least in part, focus on reducing community transmission, either by reducing transmission routes between linked regions, or focusing on prevention measures such as

drinking and using clean water, washing hands with soap more often, and using adequate sanitation in regions

148 with high case numbers.

149 One challenge to cholera containment may be the fact that *V. cholerae* strains circulating in Africa have reportedly

been expanding the number of antibiotic classes to which they confer resistance [8]. This is cause for concern, as

these antibiotic drugs have long been used for treating severe cholera cases. Our results show the presence of at

152 least some resistant isolates in all drugs tested, highlighting the need for continued monitoring of antimicrobial

resistance, even when cases seem to be derived from the same persistent lineage.

Despite the clear implications of our genomic findings for containment of the T12 lineage, genomic surveillance 154 in low-resource public health settings continues to be challenging, in part because samples are not always collected 155 and preserved with sequencing in mind. For example, we found that less than 30% of V. cholerae isolates 156 sequenced in this study produced a high-quality genome. Because we performed only reference-based assemblies 157 to the V. cholerae O1 reference, it is possible that some of the failed samples were because they were of a different 158 serogroup (see typing results in Supplementary Data 1). However, most failed sequences are likely due to low 159 input DNA concentrations due to poor storage conditions, inappropriate transport conditions from the field to 160 NPHL, or lack of resources (i.e., transport media, technology support) needed for storage, transport, or sequencing. 161 Notably, almost all samples from 2023 failed because of lack of sequencing platform support. Investment in 162 surveillance systems that include routine whole genome sequencing may address some of these sequences, 163

164 especially those caused by poor long-term storage conditions.

165 Since the introduction of *V. cholerae* into Africa from Asia in 1961, a limited number of isolates from central and

166 western sub-region of Africa have been sequenced, with fewer than 100 (as of time of writing) sequences available

167 from Cameroon, most of which were sequenced abroad. In the present study, we greatly increase the fraction of

sequences generated in-country, which may ultimately decrease the time between sample collection and generation of actionable genomic results. This highlights the necessity for public health authorities in low-income

countries to further develop genomic surveillance strategies of pathogens with epidemic potential such as cholera.

## 171 MATERIAL AND METHODS

#### 172 Data Availability

173 Raw data for all sequenced isolates is available under NCBI BioProject accession: PRJNA954566. Source data

files have been provided for all figures as Supplementary Data 1-4. Laboratory protocol and bioinformatics

175 pipeline used for analysis are publicly available at https://github.com/HopkinsIDD/minion-vc.

#### 176 Ethics Statement

Samples used in this study were collected as part of ongoing outbreak investigations for the monitoring of cholera in Cameroon. Only leftover clinical diagnostic samples (already stored as bacterial isolates) were used for sequencing. No identifying patient information was included in this study, and only bacterial isolates were sequenced (i.e., no chance of sequencing human data). Ethical approval was granted by the University of Buea (Cameroon) Faculty of Health Sciences Institutional Review Board (2023/1974-02/UB/SG/IRB/FHS).

#### 182 Sample selection, collection, and cholera confirmation

183 In this study, we selected randomly from all *V. cholerae* isolates stored at NPHL from the 2018-2023 outbreaks

184 (see **Table 1**). We excluded samples for which we did not obtain *V. cholerae* growth after replating the isolate on

185 TCBS and Muller Hinton media.

These isolates were originally collected and cultured as follows: isolates were generated from fresh (within 24-48 186 hours of symptom onset) stool samples from suspected cholera cases during the three most recent cholera 187 outbreaks in Cameroon (starting in 2018, 2020, and 2021). These samples were initially collected in sterile screw-188 capped stool recipients by laboratory technicians and trained community healthcare workers in communities and 189 health facilities in districts that notified suspected cases. Specifically, two sterile cotton swabs were immersed into 190 the stool and aseptically inserted into a screw tube containing 10 ml Cary-Blair transport medium. For children 191 192 who could not produce stools on demand, samples came from rectal swabs collected using moist cotton swabs and dipped into Cary-Blair transport media. Samples were placed in a triple package insulated box and transported 193 to the National Public Health Laboratory (NPHL) in Cameroon within a maximum of 48 hours. 194

At NPHL, each stool sample collected during the outbreaks was first directly inoculated on thiosulfate citrate bile 195 salt sucrose (TCBS) and incubated at 37°C for 24 hours. Immediately after culturing the first TCBS dish, sample 196 was introduced into alkaline peptone water (APW) and incubated at 37°C for 8 hours. A second TCBS dish was 197 then inoculated with the stool sample enriched on APW and incubated at 37°C. After 24 hours of incubation, 198 characteristic V. cholerae colonies were selected and finally subcultured on Muller Hinton agar and incubated at 199 37°C for 24 hours. Colonies resulting from this culture on Muller Hinton medium were resuspended in 5ml of 200 sterile saline solution to obtain a 0.5 McFarland inoculum and used for the phenotypic identification of V. cholerae 201 based on biochemical characteristics and serotyping. Biochemical identification was done using API 20E 202 biochemical galleries (BioMerieux, USA). Each well was inoculated using a sterile pipette and then incubated for 203 16-24 hours at 37°C and the reactions were noted as either positive or negative. Serotyping was done by 204 agglutination tests using commercial V. cholerae Ogawa and Inaba antisera kits (Deben Diagnostics, India) 205 according to the manufacturer instructions. 206

#### 207 Antibiotic Susceptibility Testing

Antibiotic susceptibility testing was performed by disk-diffusion method [15] for the following antimicrobial 208 drugs: amoxicillin (20µg), amoxicillin/clavulanic acid (10-20µg), cephalotin (20µg), cefotaxim (30µg), 209 chloramphenicol (30µg), gentamicin (15µg), nalidixic acid (20µg), doxyciclin (30µg), tetracycline (30µg), 210 polymixin B, azythromicin (15µg) and ciprofloxacin (30µg). The tested antibiotics were chosen based on the 211 European Committee on Antimicrobial Susceptibility Testing (EUCAST, http://www.eucast.org). These 212 antibiotics and the agar swabbing inoculation technique described below underwent quality control using 213 214 Escherichia coli ATCC 25922 reference strains before use for V. cholerae. In brief, after 5 min of incubation of V. cholerae inoculum on Mueller Hinton agar at room temperature, antibiotic discs were applied on the medium. 215 Plates were incubated at 37°C overnight. Interpretation was done by measuring inhibition diameters around the 216 disks using a caliper. Sensitivity, resistance, or the intermediate phenotypes of the strain to antibiotics was 217 appropriate 218 interpreted applying the EUCAST guidelines. Abricate software

219 (www.github.com/tseemann/abricate) and the Comprehensive Antibiotic Resistance Database (CARD) 220 (www.card.mcmaster.ca/analyze/rgi) online tool were used to identify genes and single-nucleotide

221 polymorphisms (SNPs) associated with antibiotic resistance.

#### 222 DNA extraction and quantification

DNA extraction was performed at NPHL on V. cholerae isolates from the 2018 and 2020 outbreaks. Samples 223 stored at -80°C in glycerol-brain heart infusion medium were allowed to thaw at room temperature, and then were 224 re-plated on Mueller Hinton agar (MH) and TCBS. Samples from the 2021 outbreak were directly plated on TCBS 225 culture medium. All plates were incubated at 37°C overnight. 2 to 4 colonies were then inoculated into 4ml of 226 227 sterile Bacto<sup>TM</sup>Peptone (alkaline peptone water) and incubated at 37°C overnight. A shaker was used during this incubation. Afterwards 1ml of cloudy culture media was used for DNA extraction using the Oiagen OIAmp DNA 228 Mini Kit, with a final elution volume of 150 µL. The extracted DNA concentration was directly measured using 229 a Quantus Fluorometer, following the instructions of the manufacturer. 230

#### 231 Oxford Nanopore library construction and sequencing

232 Library preparation and sequencing was performed at NPHL in Yaoundé, Cameroon. We used modified version

of the Oxford Nanopore 1D Native barcoding genomic DNA (with EXP-NBD104, EXP-NBD114, and SQK-

LSK109) as described in Ekeng et al. [12]. The extracted DNA was diluted to 1  $\mu$ g in 49  $\mu$ L with nuclease-free

water and  $48\mu$ L of this solution was used for library preparation. For samples with a DNA concentration below 20 ng/µL, 48µl of extracted DNA was used regardless of the final amount (<1µg). Sequences were prepared in 6

237 different batches (Supplementary Data 1).

After library preparation following the Oxford Nanopore protocol, we diluted the final library to a final volume

of 12  $\mu$ L in Elution Buffer and combined with 37.5  $\mu$ L Sequencing Buffer and 25.5  $\mu$ L Loading Beads. This

240 mixture was loaded onto a primed R9.4.1 FLO-MIN106 Oxford Nanopore MinION flow cell. For each sequencing

241 library, the MinION was run for 48 hours.

#### 242 Reference-based genome assembly

As described in Ekeng et al. [12], sequencing runs were basecalled using Guppy version 4.0.4 with the flip-flop 243 (dna r9.4.1 450bps fast.cfg). Porechop (https://github.com/rrwick/Porechop) was 244 model used for demultiplexing and adapter removal, and we filtered out low quality sequencing reads using Filtlong 245 (https://github.com/rrwick/Filtlong) with the following options: 'filtlong --keep percent 90 --target bases 246 247 80000000'.

Using the resulting filtered FASTQ files, we performed reference-based assembly following the bioinformatics pipeline available here: <u>https://github.com/HopkinsIDD/minion-vc</u>. We used the N16961 strain (Genbank accession: AE003852/AE003853) as a reference for these seventh pandemic O1 sequences and required coverage of at least 100x to call a base at each site across the genome. Assemblies with less than 97% coverage of the reference genome and a median read depth (across the complete N16961 reference genome) below 100 were excluded from subsequent phylogenetic analysis.

#### 254 Vibrio cholerae typing

255 Typing was performed by mapping reads from sequenced isolate to reference genes ctxA, tcpA\_classical,

tcpA\_eltor, toxR, wbeO1, and wbfO139, with Genbank accession numbers AF463401, M33514.1, KP187623.1,

KF498634.1, KC152957 and AB012956, respectively [16]. We mapped filtered reads to each reference using

258 minimap2 version 2.17 [17] using scripts included as part of the publicly available bioinformatics pipeline noted

- above. Using samtools, we counted the number of reads mapping to each gene reference, the fraction of the gene
- covered by mapped reads, and the depth of coverage of each site across the reference gene of interest.

## 261 Maximum likelihood estimation

- We concatenated reference-based assemblies generated during this study to 1323 previously published *V. cholerae* O1 whole genome sequences [8–10, 12, 18, 19] also assembled to the N16961 reference. These background sequences were selected to represent most of the publicly available whole genome sequences (**Supplementary Data 3**). We masked recombinant sites in these sequences as previously described, first with a selection of fixed masked sites from Weill et al. 2017 [8] (available at: https://figshare.com/s/d6c1c6f02eac0c9c871e) and then
- using Gubbins version 3.2.1 [20]. To generate maximum likelihood trees, we ran IQ-TREE version 1.4.4 [21]
- using the ModelFinder [22] option, which identified TVM+F+ASC+G4 as the best nucleotide substitution model,
- and 1000 ultrafast bootstrap replicates [23] . The final tree was rooted on the taxa labeled 5174\_7\_5 (accession:
- ERR025382), as described in Weill et al. 2019 [9] and Ekeng et al. 2021 [12]. We visualized the resulting tree in
- 271 FigTree version 1.4.4 (<u>http://tree.bio.ed.ac.uk/software/figtree/</u>).

# 272 **REFERENCES**

- Hu D, Liu B, Feng L, Ding P, Guo X, *et al.* Origins of the current seventh cholera pandemic. *Proc Natl Acad Sci U S* A 2016;113:E7730–E7739.
- Mengel MA, Delrieu I, Heyerdahl L, Gessner BD. Cholera outbreaks in Africa. *Curr Top Microbiol Immunol* 2014;379:117–144.
- Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. *PLoS Negl Trop* Dis 2015;9:e0003832.
- UNICEF. Cholera epidemiology and response factsheet Cameroon.
  https://www.plateformecholera.info/attachments/article/220/UNICEF-Factsheet-Cameroon-EN-FINAL.pdf (2013, accessed 6 November 2023).
- Rapport de Situation N°15, Épidémie de choléra dans la région de l'Extrême-Nord, 17 septembre 2019. Ministere De
  La Sante Publique. https://reliefweb.int/report/cameroon/rapport-de-situation-n-15-pid-mie-de-chol-ra-dans-la-r-gion de-l-extr-me-nord-17 (18 September 2019, accessed 22 November 2023).
- Rapport Situation Choléra Cameroun N°12. *CCOUSP*. https://www.ccousp.cm/download/rapport-situation-choleracameroun-n12/ (2022, accessed 22 November 2023).
- ACAPS Briefing note: Cameroon Increase in cholera cases (29 June 2023). ACAPS.
  https://reliefweb.int/report/cameroon/acaps-briefing-note-cameroon-increase-cholera-cases-29-june-2023 (29 June 2023, accessed 22 November 2023).
- Weill F-X, Domman D, Njamkepo E, Tarr C, Rauzier J, *et al.* Genomic history of the seventh pandemic of cholera in Africa. *Science* 2017;358:785–789.
- Weill F-X, Domman D, Njamkepo E, Almesbahi AA, Naji M, *et al.* Genomic insights into the 2016-2017 cholera
  epidemic in Yemen. *Nature* 2019;565:230–233.
- Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, *et al.* Evidence for several waves of global transmission
  in the seventh cholera pandemic. *Nature* 2011;477:462–465.
- 11. Benamrouche N, Belkader C, Njamkepo E, Zemam SS, Sadat S, et al. Outbreak of Imported Seventh Pandemic

- 297 Vibrio cholerae O1 El Tor, Algeria, 2018. *Emerg Infect Dis* 2022;28:1241–1245.
- Ekeng E, Tchatchouang S, Akenji B, Issaka BB, Akintayo I, *et al.* Regional sequencing collaboration reveals
  persistence of the T12 Vibrio cholerae O1 lineage in West Africa. *Elife*;10. Epub ahead of print 18 June 2021. DOI:
  10.7554/eLife.65159.
- Ievy S, Hoque MN, Islam MS, Sobur MA, Ballah FM, *et al.* Genomic characteristics, virulence, and antimicrobial
  resistance in avian pathogenic Escherichia coli MTR\_BAU02 strain isolated from layer farm in Bangladesh. *J Glob Antimicrob Resist* 2022;30:155–162.
- 14. **QGIS Development Team**. *QGIS Geographic Information System*. QGIS Association. https://www.qgis.org.
- Hudzicki J. Kirby-Bauer disk diffusion susceptibility test protocol. https://asm.org/getattachment/2594ce26-bd44 47f6-8287-0657aa9185ad/Kirby-Bauer-Disk-DiffusionSusceptibility-Test-Protocol-pdf.pdf (accessed 6 November
  2023).
- 308 16. Greig DR, Schaefer U, Octavia S, Hunter E, Chattaway MA, *et al.* Evaluation of Whole-Genome Sequencing for
  309 Identification and Typing of Vibrio cholerae. *J Clin Microbiol*;56. Epub ahead of print November 2018. DOI:
  310 10.1128/JCM.00831-18.
- 311 17. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* 2018;34:3094–3100.
- Bwire G, Sack DA, Almeida M, Li S, Voeglein JB, *et al.* Molecular characterization of Vibrio cholerae responsible
  for cholera epidemics in Uganda by PCR, MLVA and WGS. *PLoS Negl Trop Dis* 2018;12:e0006492.
- Irenge LM, Ambroise J, Mitangala PN, Bearzatto B, Kabangwa RKS, *et al.* Genomic analysis of pathogenic
  isolates of Vibrio cholerae from eastern Democratic Republic of the Congo (2014-2017). *PLoS Negl Trop Dis* 2020;14:e0007642.
- Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, *et al.* Rapid phylogenetic analysis of large samples of
  recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* 2015;43:e15.
- Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for
  estimating maximum-likelihood phylogenies. *Mol Biol Evol* 2015;32:268–274.
- 321 22. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for
  322 accurate phylogenetic estimates. *Nat Methods* 2017;14:587–589.
- Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, et al. IQ-TREE 2: New Models and
  Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* 2020;37:1530–1534.
- 325 24. Dengo-Baloi LC, Semá-Baltazar CA, Manhique LV, Chitio JE, Inguane DL, *et al.* Antibiotics resistance in El Tor
  326 Vibrio cholerae 01 isolated during cholera outbreaks in Mozambique from 2012 to 2015. *PLoS One* 327 2017;12:e0181496.
- Fuesslin V, Krautwurst S, Srivastava A, Winter D, Liedigk B, *et al.* Prediction of Antibiotic Susceptibility Profiles
  of Vibrio cholerae Isolates From Whole Genome Illumina and Nanopore Sequencing Data: CholerAegon. *Front Microbiol* 2022;13:909692.

Parvin I, Shahunja KM, Khan SH, Alam T, Shahrin L, *et al.* Changing Susceptibility Pattern of Vibrio cholerae
 O1 Isolates to Commonly Used Antibiotics in the Largest Diarrheal Disease Hospital in Bangladesh during 2000 2018. *Am J Trop Med Hyg* 2020;103:652–658.